To Be Discontinued Injection Oncology
Pemetrexed Disodium Injectio · 330 days since initial FDA posting
Brand: ALIMTA
FDA lists Pemetrexed Disodium Injectio as To Be Discontinued (Eli Lilly and Co.).
No availability text on this FDA row.
Pemetrexed Disodium Injection: To Be Discontinued
FDA availability text is not recorded on this row. Contact your pharmacist if you are affected.
Shortage Details
- Generic Name
- Pemetrexed Disodium Injection
- Manufacturer
- Eli Lilly and Co.
- Dosage Form
- Injection
- Presentation
- Alimta, Injection, 100 mg/4 mL (NDC 0002-7640-01)
- Package NDC
- 0002-7640-01
Status & Timeline
- Status
- To Be Discontinued
- First Reported
- Oct 16, 2025
- Last Updated
- Oct 16, 2025
- Therapeutic Category
- Oncology
Row fields from the FDA Drug Shortages database via openFDA.
Shortage Reason
Discontinuation of the manufacture of the drug
Nearby, Other Pemetrexed Shortage Records
FDA reason on file: Discontinuation of the manufacture of the drug. General shortage guidance lives on the tracker hub.